Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 133 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 M3n0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NESwSWcxNTFyIN88US=> NFPXbG8xNTRiZB?= MWTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MViyOlcxOjd6NB?=
HepG2 NG\ndZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDESFJQOC1zMDFOwG0> M4HKNlAuPCCm MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV:yOlcxOjd6NB?=
HT29 NFzO[VRHfW6ldHnvckBCe3OjeR?= NID5UIU2OMLibl2= M3\BSlI1NTd{IHi= NUe3VoJwcW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2ViMzDh[pRmeiB2ONMgbOKh M2\NRVI3PzB{N{i0
HepG2 MX\GeY5kfGmxbjDBd5NigQ>? MYW1NOKhdk1? M{P4blI1NTd{IHi= M1vnZYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhOjUEoHlCpC=> MVOyOlcxOjd6NB?=
HCC827 NGDGSnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmmzOU84NjVxMUCgcm0> MmLiO|LDqGh? NWK0UHhkTE2VTx?= NFTQU25mdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= MYeyOlY4PTR6NB?=
A549  NYTyN5ZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWP1T45pOTBxMUWvNlAhdk1? NUD4VnYxPzMEoHi= NYG5fIo2TE2VTx?= NVrPb2t3\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= NES3XoQzPjZ5NUS4OC=>
NCI-H460  NWq2XIFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjSZ2s3OTBxMkCvN|Ahdk1? M2X0dlczyqCq MlzESG1UVw>? MYLlcohidmOnczD0bIUh[W62aYDyc4xq\mW{YYTpeoUh\W[oZXP0JI9nKGW{bH;0bY5q[g>? MUeyOlY4PTR6NB?=
J89GFP MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrOUVZzTE2VT9Mg NUPIcHFyTUN3ME20PU45PSEEsTCxNk43PSCwTR?= NEjRPY8zPjV4M{W2PC=>
THP89GFP MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPmbVJGTE2VT9Mg MXLFR|UxRTF7LkO0JOKyKDZwNEOgcm0> MoD6NlY2PjN3Nki=
SK-NEP-1 M4jxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnaboNmOC5yMfMAl|ExNjBizszN MnvzNlQhcA>? NVzpSZFKTE2VT9Mg MVjJR|UxRTd4LkO0JI5O NU\XXpVmOjZzN{[yNVk>
G401 MmHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnWUXMzOC5yMfMAl|ExNjBizszN NGHsRYMzPCCq M1fzSWROW00EoB?= MUDJR|UxRTF2Mz6wNkBvVQ>? NVfQT2ZoOjZzN{[yNVk>
SK-NEP-1 M1HmSWNmdGxiVnnhZoltcXS7IFHzd4F6 M{jUOlUxKG6P M1rMRVHjiJN2IHS= M3;0NWROW00EoB?= NHPaRlNz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M3HTWVI3OTd4MkG5
G401 M2XZ[2NmdGxiVnnhZoltcXS7IFHzd4F6 NFLBN3E2OCCwTR?= MWGx5qCUPCCm NFuzVVRFVVORwrC= M4noRpJm\HWlZYOgZ4VtdCC|dYL2bZZidCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>? M3ewc|I3OTd4MkG5
SK-NEP-1 MWfBdI9xfG:|aYOgRZN{[Xl? NE\Ue3k2OC9zMECgcm0> MnTJNlQhcA>? MXzEUXNQyqB? M3TGVIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIjZeWUzPjF5NkKxPS=>
G401 M4jsXmFxd3C2b4Ppd{BCe3OjeR?= M3njR|UxNzFyMDDuUS=> MmftNlQhcA>? MofGSG1UV8Li MVrpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3;oeVI3OTd4MkG5
SK-NEP-1 NGr3Rm5HfW6ldHnvckBCe3OjeR?= NF7LfmU2OC9zMECgcm0> NH2xT4szPCCq NH6wNXFFVVORwrC= NUP0[nFme2ixd4OgeIhmKGmwZIXjeIlwdiCxZjDEUmEh\nKjZ33lcpRifGmxbh?= NUnVOG9kOjZzN{[yNVk>
G401 NYDJ[FR3TnWwY4Tpc44hSXO|YYm= NF3OcmQ2OC9zMECgcm0> M3jaTlI1KGh? NUPlZ2czTE2VT9Mg M{XzN5Npd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NUO1TIloOjZzN{[yNVk>
SK-NEP-1 MnPGSpVv[3Srb36gRZN{[Xl? MoSxOVAwOTByIH7N MoPWNlQhcA>? NUfHepZXTE2VT9Mg NXv2cVRVcW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? NFjVXHYzPjF5NkKxPS=>
G401 MljMSpVv[3Srb36gRZN{[Xl? NXv1UpJ4PTBxMUCwJI5O NFr0bYIzPCCq MmewSG1UV8Li MkWybY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> MXuyOlE4PjJzOR?=
RPMI 8226 MX;D[YxtKFO3co\peoFtKEG|c3H5 NXO3PGRJOi92L{[gcm0> NE\X[G41QOLCiXi= NIm1dXpqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MV6yOlAxODJ7Mh?=
OPM2 M2GxbWNmdGxiU4Xyeol3[WxiQYPzZZk> M37ZUFIwPC94IH7N M{O5TlQ56oDLaB?= NHyyWoRqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq NUPxbJo4OjZyMECyPVI>
U266 MWXD[YxtKFO3co\peoFtKEG|c3H5 MoDiNk81NzZibl2= NX\p[XhsPDkkgJno MV3pcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp MYSyOlAxODJ7Mh?=
H929 NGjoVZBE\WyuIGP1dpZqfmGuIFHzd4F6 M3\XUVIwPC94IH7N MorDOFjjiImq NVKyRVl2cW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NY\NSJIxOjZyMECyPVI>
RPMI 8226  Mn3PRZBweHSxc3nzJGF{e2G7 Mm\IOQKBkW6P MUWyOE81QCCq MlTubY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MoHFNlYxODB{OUK=
HCC827 NYPWUnRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHlNVAhdk1? NILJXHE1QCCq M2faSGROW09? MnXJ[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB? M{[xVVI2QTR2NkG3
NCI-H23 NGTaboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCxNEBvVQ>? M3fBVlQ5KGh? NYnQdlJ6TE2VTx?= NF3SZWtmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= NIfyem0zPTl2NE[xOy=>
AML3 NIm3W|JHfW6ldHnvckBCe3OjeR?= MYKwMVEh|ryP Mm[4NlTDqGh? MWXpcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1XH[VI2PjF{OUSx
ML-1 M2LpRWZ2dmO2aX;uJGF{e2G7 M3rC[VAuOSEQvF2= MYiyOOKhcA>? M1:yO4lv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHvBNG0zPTZzMkm0NS=>
RPMI-8226vr10  MmfISpVv[3Srb36gRZN{[Xl? M4HCelAuOSEQvF2= NWTrOXI1OjUEoHi= M4ewWYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MUeyOVYyOjl2MR?=
ML-1 M2LCUmZ2dmO2aX;uJGF{e2G7 MXSxJO69VQ>? M4fx[VI1yqCq NWnqS4lScW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ> NGmwW5MzPTZzMkm0NS=>
RPMI-8226vr10  NXz3cXp[TnWwY4Tpc44hSXO|YYm= NGLRRlQyKM7:TR?= NH7pe2EzPMLiaB?= MWnpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk M{Xy[FI2PjF{OUSx
SK-N-BE (2) MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnrZVAzPOLCiXi= NEDwR2hKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= NFOwZmszPTNyOEmxOi=>
SK-N-BE (2), PAN  MK M4jmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrHNlTjiImq MXfJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? NHXKeJUzPTNyOEmxOi=>
SK-N-BE (2), MK  PAN NUDwVmxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:yOQKBkWh? NGDqV|NKSzVyPUO4Nk4x6oDLwsJihKk1Oy5{IH7N MXqyOVMxQDlzNh?=
SK-N-AS M2TJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vGTFI16oDLaB?= NG\pZXBKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?= NFiwToIzPTNyOEmxOi=>
SK-N-DZ Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUiyOQKBkWh? MmnsTWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1? MmrUNlU{ODh7MU[=
Caki-1 NGjMWYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{WyPVExNzJ3L{WwJI5O NV7RZZFuPDhiaB?= MUXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NH2zXlYzPTJ5OUG5NS=>
ACHN NV3ZXJhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHNRpNSOTBxMkWvOVAhdk1? MVG0PEBp MYTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NUfMUng4OjV{N{mxPVE>
769-P NVXjNXpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;q[lExNzJ3L{WwJI5O NGTNOoQ1QCCq NI\QV2tqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= Mn;RNlUzPzlzOUG=
786-O  NGrtb5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\SV|IyOC9{NT:1NEBvVQ>? MlfaOFghcA>? M4T4WolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= NFHu[4UzPTJ5OUG5NS=>
Caki-1 MmrvRZBweHSxc3nzJGF{e2G7 MXG1NEBvVQ>? NXW2[5dKPDhiaB?= NG\nXVNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= NXjrfXR6OjV{N{mxPVE>
ACHN M2rMZ2Fxd3C2b4Ppd{BCe3OjeR?= Ml3EOVAhdk1? MXm0PEBp MWfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>? MlftNlUzPzlzOUG=
769-P NHvJeVFCeG:ydH;zbZMhSXO|YYm= NGqxVGI2OCCwTR?= M2W4SVQ5KGh? M363Nolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NGnkS|czPTJ5OUG5NS=>
786-O  MoLtRZBweHSxc3nzJGF{e2G7 MoDBOVAhdk1? Mon2OFghcA>? MnGwbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? MXuyOVI4QTF7MR?=
Caki-1 M4n5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV60UVJWOjVxNUCgcm0> MkDuOFghcA>? NHnpN2JFVVOR MlPibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= NXPYfHNWOjVzN{[zOVQ>
ACHN M1PCU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2joXlI2NzVyIH7N MXm0PEBp MVrEUXNQ NInvPGtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NEHsWXAzPTF5NkO1OC=>
769-P M1faXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHPNlUwPTBibl2= NWnHNoZlPDhiaB?= MWPEUXNQ NHflZYVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni M2fITlI2OTd4M{W0
Caki-1 NY[2foJVS2:ub375JGZwem2jdHnvckBCe3OjeR?= NWq3c2pQPTBibl2= NXn0dHVuPy1zNDDk NI\jRm1FVVOR M1LsTpN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh NWX0flZkOjVzN{[zOVQ>
ACHN M3e3NGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? M{nSN|UxKG6P M33tflcuOTRiZB?= NEC4UXRFVVOR MmDMd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MYmyOVE4PjN3NB?=
769-P NV3kZpBsS2:ub375JGZwem2jdHnvckBCe3OjeR?= NWj3VW1PPTBibl2= M3jZOFcuOTRiZB?= Mnv5SG1UVw>? Mo\nd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MYKyOVE4PjN3NB?=
Caki-1 NYPjVFF4SXCxcITvd4l{KEG|c3H5 M2T5WlUxKG6P MmTMOFghcA>? NXHaS41XTE2VTx?= NVXF[WNOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= Mmf3NlUyPzZ|NUS=
ACHN MUfBdI9xfG:|aYOgRZN{[Xl? M1H4WVUxKG6P M1ezflQ5KGh? M{TLUGROW09? NYXQdY9{cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MlTGNlUyPzZ|NUS=
769-P NHjtUoNCeG:ydH;zbZMhSXO|YYm= M3HhVVUxKG6P M1fwWlQ5KGh? Mme2SG1UVw>? MVTpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NFrGfYozPTF5NkO1OC=>
MDA-MB-231 MnPmUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MnyxNVDDqG6P MXOzxsBl NFzRZY1FVVOR MXXhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? Mo\rNlQ5OTB2OUe=
BT-549 M4G0fG1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? MVuxNOKhdk1? MkXNN:Kh\A>? NWS4Wll4TE2VTx?= NWmwZox4[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg MnLNNlQ5OTB2OUe=
MCF-7  M1\zUG1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NWXYXYN{OTEEoH7N MVqzxsBl MmjZSG1UVw>? NHv5T49idHSncoOgZ4VtdCCvb4LwbI9td2e7wrC= MWOyOFgyODR7Nx?=
MCF-7 NWDL[49bTnWwY4Tpc44hSXO|YYm= MXW1MVUxKG6P NFj1TZYzPCCq NUjINFI3TE2VTx?= NUXHTJlQemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>? M37Fe|I1OzZ4NEC3
CTS M2XjcWFxd3C2b4Ppd{BCe3OjeR?= MnT5NQKBmzRyIH7NxsA> MoizOFghcA>? M1TTNYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXOyOFI1PDR{OR?=
OCI-AML3  MULBdI9xfG:|aYOgRZN{[Xl? MkfINQKBmzRyIH7NxsA> Ml\NOFghcA>? MYTpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mm\4NlQzPDR2Mkm=
U937 MnrNRZBweHSxc3nzJGF{e2G7 NX;IfGlnOOLCk{SwJI5OyqB? MUe0PEBp M{PCSolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3nXUFI1OjR2NEK5
PC3 M{nKZmFxd3C2b4Ppd{BCe3OjeR?= M3P0WlAuOTByIH7N MnPDNlQwPDhiaB?= NIf6eWdqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYWyR5NuOjRzNkOyN|A>
PC3-AR NIfKdXRCeG:ydH;zbZMhSXO|YYm= NUHvO2o3OC1zMECgcm0> NIewVpMzPC92ODDo M4ju[Ilv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVXvVotMOjRzNkOyN|A>
PC3 M{XmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLTNVRjOC1zMECgcm0> MX2yOE81QCCq NVraVGplcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?= NED3WVYzPDF4M{KzNC=>
PC3-AR NFnUWHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHJcHU5OC1zMECgcm0> M3;KelI1NzR6IHi= M2G2N4lv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= NU\5W3g4OjRzNkOyN|A>
PC3 NU\2WoxRTnWwY4Tpc44hSXO|YYm= MXSwMVExOCCwTR?= NG\oVJMzPCCq NHTyeWF{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM|IheHKxdHXpci=> NEGyOGkzPDF4M{KzNC=>
PC3-AR M3XL[WZ2dmO2aX;uJGF{e2G7 MoDKNE0yODBibl2= MV6yOEBp MVjzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= MYKyOFE3OzJ|MB?=
OS-RC-2 M3f4bmNmdGxiVnnhZoltcXS7IFHzd4F6 MWGwMVExODBibl2= M1XsRlI1NzR6L{eyJIg> M4PVUGROW09? MYjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFq5blgzPDF2NEezOy=>
OS-RC-2 MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLXdogzPTBibl2= NVjjemlKPDhiaB?= NInv[4pFVVOR MVLpcoR2[2W|IFeyM20h[XK{ZYP0 M{G5V|I1OTR2N{O3
OS-RC-2 NECxNWxCeG:ydH;zbZMhSXO|YYm= MYS1NEBvVQ>? M2HYS|Q5KGh? MXLEUXNQ NFLOW5BqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MX:yOFE1PDd|Nx?=
SK-N-AS NHeyfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVuw5qCUQDBibl2= NYPyd3FtPDhiaB?= MVHJR|UxRTJ5LkSgcm0> NVjiN2I3OjRyOUi3PVk>
SK-N-DZ MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XW[|DjiJN6MDDuUS=> Mn7tOFghcA>? NYrFdVl1UUN3ME2yNU46KG6P NVjzNXRzOjRyOUi3PVk>
SK-N-SH NFjW[2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlSxNQKBmzhyIH7N NETCZVI1QCCq NX[2N4RsUUN3ME23Nk4{KG6P MoHINlQxQTh5OUm=
SK-N-BE Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\0NQKBmzhyIH7N NUDXPItbPDhiaB?= NFj1WHZKSzVyPUe1MlQhdk1? NYrnZlF1OjRyOUi3PVk>
SK-N-AS MoTYRZBweHSxc3nzJGF{e2G7 MViw5qCUQDBibl2= M{LD[|Q5KGh? M2rnT5BwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> MkK1NlQxQTh5OUm=
SK-N-DZ NVHh[29mSXCxcITvd4l{KEG|c3H5 MlP5NQKBmzhyIH7N NXTPVXE1PDhiaB?= NEXjWWpxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NYTCdWlMOjRyOUi3PVk>
SK-N-SH MULBdI9xfG:|aYOgRZN{[Xl? M2\TWFDjiJN2MDDuUS=> NI\yOW41QCCq MkK2dI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MlixNlQxQTh5OUm=
SK-N-BE MVXBdI9xfG:|aYOgRZN{[Xl? M4LYUlDjiJN2MDDuUS=> MlzJOFghcA>? NIr5d2txd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MXuyOFA6QDd7OR?=
SK-N-AS MXjGeY5kfGmxbjDBd5NigQ>? NXzKRXJ2OOLCk{iwJI5O M2fu[|Q5KGh? NGC4S3JqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgZ4xm[X[jZ3Wgc4Yh[2G|cHHz[UA{KGGwZDDQRXJR M4H6VFI1ODl6N{m5
SK-N-DZ NF[0TldHfW6ldHnvckBCe3OjeR?= NWjkUXNZOOLCk{iwJI5O MUG0PEBp MlTHbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MWOyOFA6QDd7OR?=
SK-N-SH MV7GeY5kfGmxbjDBd5NigQ>? MX[w5qCUPDBibl2= NWnZSI1[PDhiaB?= MkSxbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MmDoNlQxQTh5OUm=
SK-N-BE MUDGeY5kfGmxbjDBd5NigQ>? MWGw5qCUPDBibl2= NUXVVGVEPDhiaB?= MUXpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NHTXXXczPDB7OEe5PS=>
HCC-LM3 NE\2SGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV6xMVExODBibl2= MYeyOE81QC95MjDo Ml7DSG1UVw>? MlzWbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1HRdVI1ODl|OUW2
HepG2 MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC3NU0yODByIH7N MoHaNlQwPDhxN{KgbC=> NGDDeYpFVVOR M4Dqe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3LwOFI1ODl|OUW2
SMMC-7721 NY\SV|BbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUe4SHk2OS1zMECwJI5O MXeyOE81QC95MjDo MVfEUXNQ NHiwUmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlvNNlQxQTN7NU[=
HCC-LM3 NWD6OJlkSXCxcITvd4l{KEG|c3H5 Mnq3OVAhdk1? Ml2xOFghcA>? MmfiSG1UVw>? M1y1[4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MWGyOFA6Ozl3Nh?=
HepG2 MX7BdI9xfG:|aYOgRZN{[Xl? M3XCXlUxKG6P NFXBW4w1QCCq MnvoSG1UVw>? M3TnSolv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MlPnNlQxQTN7NU[=
SMMC-7721 NFfkRVdCeG:ydH;zbZMhSXO|YYm= MVK1NEBvVQ>? M4nIOlQ5KGh? M4W2e2ROW09? MV7pcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG|ZYOgN{whQCCjbnSgPS=> MViyOFA6Ozl3Nh?=
HCC-LM3 NHPxcFhHfW6ldHnvckBCe3OjeR?= MX61NE8yODBibl2= NV[4OGZZOjRiaB?= M3XOfWROW09? NFnjUmNl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg MYSyOFA6Ozl3Nh?=
HepG2 NGG2[XBHfW6ldHnvckBCe3OjeR?= MmjnOVAwOTByIH7N MUWyOEBp MWrEUXNQ MlvZ[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= MYCyOFA6Ozl3Nh?=
SMMC-7721 MUDGeY5kfGmxbjDBd5NigQ>? MXW1NE8yODBibl2= MlHZNlQhcA>? MmjpSG1UVw>? NXr6OYpl\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> NFfvPWczPDB7M{m1Oi=>
HCC-LM3 M4nXdmZ2dmO2aX;uJGF{e2G7 M1jwVlUxNzFyMDDuUS=> MYiyOEBp NXOyNGZoTE2VTx?= MVzkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v MV:yOFA6Ozl3Nh?=
HepG2 NVOyeY5nTnWwY4Tpc44hSXO|YYm= MoXZOVAwOTByIH7N NYTEeHlFOjRiaB?= Mm[2SG1UVw>? M3TBbIRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? MYOyOFA6Ozl3Nh?=
SMMC-7721 MmTlSpVv[3Srb36gRZN{[Xl? NGXXRmI2OC9zMECgcm0> NHn1[YQzPCCq NFz6Z4xFVVOR Mn7k[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? NFXMU|QzPDB7M{m1Oi=>
FaDu NFjHbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[xNFDjiIWwTR?= MXq4M|ExNzF{IHi= MYHkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? M3HiflI1ODJ4NEiy
FaDu M{jq[mZ2dmO2aX;uJGF{e2G7 Mkn4NVAx6oDHbl2= Mom2Nk81NzhxMUKgbC=> MnfSbY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25? MX6yOFAzPjR6Mh?=
PC-3  MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\sbHNCOC1zMDFOwG0> M4rTSlI1NzR6L{eyJIg> NWrsd2ZWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3H4UFI{QTlzMkG2
LNCaP Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X1[VAuPSEQvF2= MmfaNlQwPDhxN{KgbC=> MmfjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIfMR3AzOzl7MUKxOi=>
RWPE-1  NGPNSW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSxNE0zOCEQvF2= MUiyOE81QC95MjDo MnnQbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4Dlb|I{QTlzMkG2
Capan-1 MnzYSpVv[3Srb36gRZN{[Xl? MYWyOU82OC9zMECgcm0> MVi4M|I1NzR6IHi= MkHESG1UVw>? NFXrfHZld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n MV6yN|kzOjh6Nh?=
L3.6pl NF3TXY9HfW6ldHnvckBCe3OjeR?= M3nl[|I2NzVyL{GwNEBvVQ>? MmHxPE8zPC92ODDo MX7EUXNQ NWmwO4gz\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=> NE\4d20zOzl{Mki4Oi=>
CFPAC-1  Mn;VSpVv[3Srb36gRZN{[Xl? MXqyOU82OC9zMECgcm0> MVG4M|I1NzR6IHi= M1;PdWROW09? M4TIWYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= MnrxNlM6OjJ6OE[=
Capan-1 Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViyOU82OC9zMECgcm0> M2X3UVQ5KGh? NEjiZphFVVOR MXPy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MX:yN|kzOjh6Nh?=
L3.6pl NHWxZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LubVI2NzVyL{GwNEBvVQ>? MUi0PEBp Mk\XSG1UVw>? M1vyOJJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIrnbW8zOzl{Mki4Oi=>
CFPAC-1  M{m4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH64TYMzPS93MD:xNFAhdk1? M2TMWlQ5KGh? Mly4SG1UVw>? NXHrRo1{emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVTwS2pEOjN7MkK4PFY>
Capan-1 M1rafWFxd3C2b4Ppd{BCe3OjeR?= NYPOXoZGOjVxNUCvNVAxKG6P M372UVQ5KGh? MoTMSG1UVw>? NInlRoNqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFPDVokzOzl{Mki4Oi=>
L3.6pl M{\Pc2Fxd3C2b4Ppd{BCe3OjeR?= MmjHNlUwPTBxMUCwJI5O NXjxOHhkPDhiaB?= M2nWXWROW09? M4LLNolv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYHnfZhjOjN7MkK4PFY>
CFPAC-1  MXrBdI9xfG:|aYOgRZN{[Xl? Mk\wNlUwPTBxMUCwJI5O M1XrSFQ5KGh? MUTEUXNQ MkjHbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWGyN|kzOjh6Nh?=
HN22 NFHYWVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMVIxKG6P NU\wSXBZOjRxNEigbC=> M125U2ROW09? MlW0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> MVqyN|g4PzJ|NR?=
HSC4  NIDWRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWewMVIxKG6P Mkf0NlQwPDhiaB?= NFfGdFBFVVOR M2rsVIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NU\HWo5MOjN6N{eyN|U>
HN22 M3vZTWFxd3C2b4Ppd{BCe3OjeR?= NHLEUlYxNTJyIH7N NGDOeXg1QCCq NEDxU3NFVVOR MVPpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MYeyN|g4PzJ|NR?=
HSC4  MV7BdI9xfG:|aYOgRZN{[Xl? MX2wMVIxKG6P NYHnelR7PDhiaB?= M4DITmROW09? M2j2[Ylv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M1K4N|I{QDd5MkO1
HN22 NXz4eFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[wMVIxKG6P MYC0PEBp MXvEUXNQ NUDxUnV1cW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh MmnHNlM5Pzd{M{W=
HSC4  MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf6eGFQOC1{MDDuUS=> MUG0PEBp MlTxSG1UVw>? NWezXnJ1cW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh NWHzfpRTOjN6N{eyN|U>
HN22 MUHGeY5kfGmxbjDBd5NigQ>? M1nlVFAuOjBibl2= M{fnVlQ5KGh? M1;BbmROW09? MWnzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= NILwTWQzOzh5N{KzOS=>
HSC4  NXHNZWlyTnWwY4Tpc44hSXO|YYm= M1T1RVAuOjBibl2= NUXOeXB{PDhiaB?= MXzEUXNQ NGfGR|d{fXCycnXzd4V{KFOyMTDlfJBz\XO|aX;uxsA> MXWyN|g4PzJ|NR?=
Cal62 M{myOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GwdGlEPTB;M{OgxtEhPCCwTR?= M4jIRVI{QDJ2ME[0
Hth7 M2K0OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:1WWlEPTB;MUWgxtEhOiCwTR?= NWjxcodROjN6MkSwOlQ>
Hth83 NUHXWldNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\RdGlEPTB;M{SgxtEhPSCwTR?= NH;keGMzOzh{NEC2OC=>
C643 NUTlb|d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTdzINMxJFExKG6P M4nJeVI{QDJ2ME[0
SW1736 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTN3INMxJFghdk1? NGPSO3kzOzh{NEC2OC=>
T241 NV;tZplyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHVTWM2OD14NTFCtUA4KG6P MkHlNlM5OjRyNkS=
T351 M2nSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TFcGlEPTB;NUCgxtEhOTBibl2= MVSyN|gzPDB4NB?=
BHP2-7 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP2TWM2OD1|NzFCtUA3KG6P M{D0clI{QDJ2ME[0
T238 NELHcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFuNUCwJOKyKDJyMDDuUS=> M2DMbFI{QDJ2ME[0
HCT8 NXeyO4JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\YO|IhcA>? MUXEUXNQ NXi5UFJyUUN3ME2xNk466oDLwsJihKkyNjlibl2= NWfJdIVoOjN{OUmzPFg>
H630 M1LJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jT[lczKGh? MlLPSG1UVw>? MV\JR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? M1vPdlI{Ojl7M{i4
cH630 5-FU-res Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfwSnk4OiCq MVPEUXNQ NYDI[GE4UUN3ME2xOU426oDLwsJihKkyNjJibl2= NXPLNpRuOjN{OUmzPFg>
HCT116 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDoO|IhcA>? NVPG[IxMTE2VTx?= M2fRb2lEPTB;MUCuO-KBkcLz4pEJNk4zKG6P Mmi3NlMzQTl|OEi=
HCT116 p53−/− MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXyUGIxPzJiaB?= NYqxOZhpTE2VTx?= NHLGUoZKSzVyPUiuOwKBkcLz4pEJNU44KG6P Mke4NlMzQTl|OEi=
dHCT116 p21−/− Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\oSFd2PzJiaB?= NHi0NZRFVVOR M4LNe2lEPTB;NT655qCKyrIkgJmxMlMhdk1? NEj4bGQzOzJ7OUO4PC=>
HT29 MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi3NkBp NFLP[YhFVVOR MYLJR|UxRTF4LkRihKnDueLCiUKuN{BvVQ>? M{n6TFI{Ojl7M{i4
LoVo NWnCb2lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PMNlczKGh? NW\xNY5DTE2VTx?= NX;SbphOUUN3ME21MlHjiIoEsfMAjVAvPiCwTR?= NH3IflgzOzJ7OUO4PC=>
RKO NG[3N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWWyVGRbPzJiaB?= MlW3SG1UVw>? M4m4UWlEPTB;Nz655qCKyrIkgJmyMlIhdk1? Mo\vNlMzQTl|OEi=
SW480 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYW3NkBp MnnMSG1UVw>? NXq0VpJNUUN3ME2xO{426oDLwsJihKkxNjhibl2= NEPUVo8zOzJ7OUO4PC=>
eSW620 NUTo[nJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL6O|IhcA>? NIjvdZBFVVOR NUKz[nhDUUN3ME25MlHjiIoEsfMAjVIvOSCwTR?= NW\xSXV7OjN{OUmzPFg>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DNMT1 / EZH2; 

PubMed: 19279403     


Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control.

caspase-8 / cleaved caspase-8 / Sp1; 

PubMed: 27738323     


The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. 

c-Myc / IRF4; 

PubMed: 27738323     


RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting.

Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; 

PubMed: 28915627     


Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1.

RAD51 / BRCA1 / CHK1 / RPL13a; 

PubMed: 24244429     


CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells.

H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; 

PubMed: 31071955     


Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.

19279403 27738323 28915627 24244429 31071955
Immunofluorescence
Synaptophysin / NACM; 

PubMed: 28915627     


Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm.

α-tubulin / Acetyl-α-tubulin; 

PubMed: 29983882     


CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm.

BiP; 

PubMed: 23544167     


Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

ATF4; 

PubMed: 23544167     


HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

IRE1α / S724-IRE1α; 

PubMed: 23544167     


Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.

28915627 29983882 23544167
Growth inhibition assay
Cell viability; 

PubMed: 27738323     


The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.

27738323
In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03632317 Withdrawn Drug: Panobinostat|Drug: Everolimus Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center October 2019 Phase 2
NCT03982134 Withdrawn Drug: PDR001|Drug: Panobinostat Melanoma|Non Small Cell Lung Cancer Muhammad Furqan|Novartis Pharmaceuticals|University of Iowa September 2019 Phase 1
NCT03515915 Recruiting -- Patients With Recurrent or Refractory Multiple Myeloma University Hospital Montpellier|Poitiers University Hospital April 23 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID